Quarterly report pursuant to Section 13 or 15(d)

Intangibles (Narrative) (Details)

v3.21.2
Intangibles (Narrative) (Details) - USD ($)
$ in Thousands
9 Months Ended
May 13, 2021
Sep. 30, 2021
Sep. 30, 2020
Finite-Lived Intangible Assets [Line Items]      
Purchase of intangible asset   $ 400 $ 1,000
Qbrexza [Member] | Journey [Member] | Dermira, Inc. a subsidiary of Eli Lilly [Member]      
Finite-Lived Intangible Assets [Line Items]      
Purchase of intangible asset $ 12,500    
Payments of milestones $ 144,000    
Percentage of royalty amounts diminution in the event of loss of exclusivity 50.00%    
Allowance for sales returns $ 1,400    
Intangible assets, amortization period 7 years